Projects per year
Personal profile
Education
-
2005-2012 Ph.D., Department of Pharmacology, National Taiwan University
-
2000-2005 B.S., School of Pharmacy, National Taiwan University
Experience
- 2026.02- Professor, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University
- 2020.08-2026.01 Associate Professor, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University
- 2016.03-2020.07 Assistant Professor, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University
- 2016.01-2016.03 Postdoctoral Research Fellow, Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
- 2013.07-2014.02 Postdoctoral Research Scholar, Academia Sinica
- 2012.02-2013.06 Postdoctoral Research Fellow, National Taiwan University
Awards
- 2022 Outstanding Teaching Award, College of Medicine, Taipei Medical University
- 2019 Young Researcher Award, Taipei Medical University
- 2018 Outstanding International Journal Publication Award, Taipei Medical University
Research Interests
- 藥理及毒理
- 藥學
Fingerprint
Dive into the research topics where Chun-Han Chen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Cinobufotalin調控管腔型膀胱癌代謝重編程、癌幹細胞特性與免疫調節之分子標的與藥理機轉探討(1/3)
Chen, C.-H. (PI)
8/1/26 → 7/31/27
Project: A - Government Institution › b - National Science and Technology Council
-
Cinobufotalin 調控膀胱癌細胞上皮－間質轉化與癌幹細胞特性之分子作用機轉探討
Chen, C.-H. (PI)
7/1/26 → 2/28/27
Project: A - Government Institution › b - National Science and Technology Council
-
Targeting Pparγ by Bufadienolides as a New Therapeutic Strategy in Luminal-Type Bladder Cancer
Chen, C.-H. (PI)
8/1/25 → 7/31/26
Project: A - Government Institution › b - National Science and Technology Council
-
Development of Anti-Bladder Cancer Therapy from Bufadienolides by Targeting Metabolic Reprogramming.
Chen, C.-H. (PI)
8/1/24 → 7/31/25
Project: A - Government Institution › b - National Science and Technology Council
-
Investigating the Therapeutic Potential and Molecular Mechanism of Natural Products in Pediatric High-Grade Gliomas
Chen, C.-H. (PI)
8/1/23 → 7/31/24
Project: A - Government Institution › b - National Science and Technology Council
-
Abemaciclib impairs glioblastoma sphere formation by targeting the GSK3β-mediated transcriptional regulation of CD44 and TCF7L2
Liang, M. L., Chen, C. H., Lin, Y. C., Lin, Y. C., Liu, Y. R., Ding, Y. H., Chu, C. Y. & Hsieh, T. H., Oct 2025, In: Cancer Gene Therapy. 32, 10, p. 1120-1132 13 p.Research output: Contribution to journal › Article › peer-review
2 Link opens in a new tab Citations (Scopus) -
FGFR inhibitors promote the autophagic degradation of IFN-γ-induced PD-L1 and alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in non-muscle-invasive bladder cancer
Lin, Y. C., Chu, C. Y., Hsieh, T. H., Lin, B. J., Liou, J. P., Yen, Y. & Chen, C. H., Dec 2025, In: Cell Death and Disease. 16, 1, 485.Research output: Contribution to journal › Article › peer-review
Open Access7 Link opens in a new tab Citations (Scopus) -
Hinokiflavone is a novel CK2 inhibitor promoting apoptosis and synergizing with chemotherapeutic agents in cisplatin resistant bladder cancer cells
Hsieh, T. H., Kuo, H. P., Chen, M. C., Lin, Y. C., Lin, B. J., Hsu, K. C. & Chen, C. H., Dec 2025, In: Scientific Reports. 15, 1, 20922.Research output: Contribution to journal › Article › peer-review
Open Access6 Link opens in a new tab Citations (Scopus) -
Correction to: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells (Cell Death & Disease, (2013), 4, 9, (e810), 10.1038/cddis.2013.330)
Chen, M. C., Chen, C. H., Wang, J. C., Tsai, A. C., Liou, J. P., Pan, S. L. & Teng, C. M., Jul 2024, In: Cell Death and Disease. 15, 7, 490.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Targeting CK1δand CK1ϵ as a New Therapeutic Approach for Clear Cell Renal Cell Carcinoma
Lin, Y. C., Sun, D. P., Hsieh, T. H. & Chen, C. H., Dec 1 2024, In: Pharmacology. 109, 6, p. 330-340 11 p.Research output: Contribution to journal › Article › peer-review
4 Link opens in a new tab Citations (Scopus)